Market Overview

UPDATE: Piper Jaffray Upgrades Threshold Pharmaceuticals to Overweight on Product Differentiation

Related THLD
Threshold Pharma Says Phase 3 Trial of TH-302 in Patients with Advanced Soft Tissue Sarcoma Will Continue as Planned
Events for the Week of Sept. 8-12

Piper Jaffray upgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Neutral to Overweight and raised the price target from $5.00 to $10.00.

Piper Jaffray noted, "We are upgrading our THLD rating to OW as a result of diligence on the differentiation of TH-302 (‘302) in 1st-line soft tissue sarcoma (STS) relative to mind-share competitor's palifosfamide (pali', Ziopharm). We believe that near-term data will enhance conviction on the broad applicability of Threshold's hypoxia-activation platform for targeting a wide range of cancer indications with the potential to substantively add/extend efficacy over standard chemotherapy (CTx). We perceive the current trading range of THLD shares to present a valuation discrepancy relative to peers and THLD's pipeline value."

Threshold Pharmaceuticals closed at $4.46 on Tuesday.

Latest Ratings for THLD

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldInitiates Coverage onBuy
Sep 2014HC WainwrightInitiates Coverage onBuy
Feb 2013Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for THLD
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Analyst Ratings

 

Related Articles (THLD)

Around the Web, We're Loving...

Get Benzinga's Newsletters